论文部分内容阅读
目的探讨二甲双胍联合磷酸西格列汀治疗2型糖尿病的疗效。方法选取2013年4月—2014年4月山西晋柴机械制造有限公司职工医院收治的2型糖尿病患者106例,随机分为A组与B组,各53例。A组患者予以二甲双胍联合吡格列酮治疗,B组患者予以二甲双胍联合磷酸西格列汀治疗。观察两组患者治疗效果、低血糖发生情况及不良反应发生情况。结果治疗前两组患者空腹血糖、餐后2h血糖、糖化血红蛋白比较,差异无统计学意义(P>0.05),治疗后B组患者空腹血糖、餐后2h血糖、糖化血红蛋白低于A组,差异均有统计学意义(P<0.05),两组患者治疗前后体质指数比较,差异无统计学意义(P>0.05);治疗前两组患者低血糖发生次数比较,差异无统计学意义(P>0.05),治疗后B组患者低血糖发生次数少于A组(P<0.05);两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论二甲双胍联合磷酸西格列汀治疗2型糖尿病的效果显著,可降低低血糖发生次数,且不良反应少,安全性高。
Objective To investigate the curative effect of metformin combined with sitagliptin phosphate on type 2 diabetes mellitus. Methods From April 2013 to April 2014, 106 patients with type 2 diabetes admitted to the staff hospital of Shanxi Jinchai Machinery Manufacturing Co. were randomly divided into A group and B group, with 53 cases in each group. Patients in group A were treated with metformin plus pioglitazone, and patients in group B were treated with metformin plus sitagliptin phosphate. The therapeutic effect, the incidence of hypoglycemia and the incidence of adverse reactions in both groups were observed. Results There was no significant difference in fasting blood glucose, postprandial 2h blood glucose and glycosylated hemoglobin between the two groups before treatment (P> 0.05). After treatment, the fasting blood glucose, postprandial 2h blood glucose and glycosylated hemoglobin in group B were lower than those in group A (P <0.05). There was no significant difference in body mass index between the two groups before and after treatment (P> 0.05). There was no significant difference in the number of hypoglycemia between the two groups before treatment (P> 0.05). After treatment, the incidence of hypoglycemia in group B was less than that in group A (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion Metformin combined with sitagliptin phosphate is effective in treating type 2 diabetes mellitus, which can reduce the incidence of hypoglycemia with less adverse reactions and high safety.